By InvitationPhase 2

Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women

United States40 participantsStarted 2018-02-06

Plain-language summary

This is a pilot study to evaluate whether targeting inflammation will help reduce markers of insulin resistance inflammation, bone resorption and physical dysfunction in elderly women with gait disturbance. Positive results of this study would lead to the development of a larger clinical trial examining the effects of this intervention on age-related dysfunction.

Who can participate

Age range

70 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria * Healthy postmenopausal women * Age ≥ 70 years Exclusion Criteria * Abnormality in any of the screening laboratory studies (see below) * Presence of significant liver or renal disease * Malignancy (including myeloma) * Malabsorption * Hypoparathyroidism * Hyperparathyroidism * Acromegaly * Cushing's syndrome * Hypopituitarism * Gastric bypass/reduction * Malabsorption issues * Crohn's * Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase or ESR) * If diabetic AND on sulfonylureas (like glipizide, glimepiride, glyburide), SGLT2 inhibitors (like dapagliflozin and empagliflozin), or insulin * Undergoing treatment with any medications that affect bone turnover, including the following: * adrenocorticosteroids (\> 3 months at any time or \> 10 days within the previous yr), anticonvulsant therapy (within the previous year), * pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal), * calcium supplementation of \> 1200 mg/d (within the preceding 3 months), * bisphosphonates (within the past 3 yrs), * denosumab, * estrogen (E) therapy or treatment with a selective E receptor modulator, or teriparatide (within the past yr). * Subjects with a fracture within the past year * Subjects taking potentially senolytic agents within the last year: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax * Subjects currently taking drugs that induce cellular senescen…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Improved 6 minute walk

Timeframe: One Month

Trial details

NCT IDNCT03430037

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-11

View on ClinicalTrials.gov More Frail Elderly Syndrome trials